Skip to content
DataLookout
Menu

NCT06527300

A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents With Advanced NUT Cancer

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 1 year 9 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jun 30, 2025 to Mar 30, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 16 words
    • Trial status changed: Unknown → Recruiting
    • Enrollment increased: 48 → 68 participants
    • Study completion pushed from Dec 30, 2025 to Aug 30, 2027
  2. Minor Changed Registry marked status Unknown; last known: Recruiting
  3. Minor Trial status: Recruiting to Unknownv2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Objective response rate (ORR)
Timeframe: Completed at least four weeks of treatment, the curative effect evaluation of CR, PR and maintain at least 4 weeks, the proportion of the subjects,up to 5 months;

Secondary (4)

Duration of response (DoR)
Disease control rate (DCR)
Progression-free survival (PFS)
time to remission (TTR)

Arms and interventions

Adult:NHWD-870 HCl 2mg ; Adolescent:NHWD-870 HCl 1.5mg/2mgExperimental

Take a fixed dose of NHWD-870 HCl tablets orally.

Drugs: NHWD-870 HCl

Sites

1 site in 1 country

  • Three Gorges Hospital Affiliated to Chongqing UniversityChongqing, China